Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.

Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.

Publication date: Aug 07, 2024

The disability-adjusted life year (DALY), a key metric for health resource allocation, encompasses morbidity through disability weights. Widely used in tuberculosis cost-effectiveness analysis (CEAs), DALYs play a significant role in informing intervention adopt/reject decisions. This study reviews the values and consistency of disability weights applied in tuberculosis-related CEAs. We conducted a systematic review using the Tufts CEA database, updated to July 2023 with searches in Embase, Scopus and PubMed. Eligible studies needed to have included a cost-per-DALY ratio, and additionally either evaluated a tuberculosis (TB) intervention or included tuberculosis-related weights. We considered all tuberculosis health states: with/without human immunodeficiency virus (HIV) coinfection, TB treatments and treatment side effects. Data were screened and extracted independently by combinations of two authors. A total of 105 studies spanning 2002-2023 across 50 countries (mainly low- and middle-income countries) were extracted. Disability weights were sourced primarily from the Global Burden of Disease (GBD; 100/165; 61%), with 17 non-GBD studies additionally referenced, along with primary derivation. Inconsistencies in the utilisation of weights were evident: of the 100 usages of GBD-sourced weights, only in 47 instances (47%) had the weight value been explicitly specified with an appropriate up-to-date reference cited (constituting 28% of all weight usages, 47/165). Sensitivity analyses on weight values had been conducted in 30% of studies (31/105). Twelve studies did not clearly specify weights or their sources; nine further calculated DALYs without morbidity. The review suggests methodological gaps in current approaches for representing important aspects of TB, including TB-HIV coinfection, treatment, drug-resistance, extrapulmonary TB and psychological impacts. We propose a set of best practice recommendations. There is a need for increased rigour in the application, sensitivity testing and reporting of TB disability weights. Furthermore, there appears a desire among researchers to reflect elements of the tuberculosis experience beyond those allowed for by GBD disability weights.

Open Access PDF

Concepts Keywords
July Ceas
Pharmacoeconomics Cost
Rethinking Daly
Tuberculosis Dalys
Disability
Effectiveness
Gbd
Intervention
Morbidity
Related
Systematic
Tuberculosis
Values
Weight
Weights

Semantics

Type Source Name
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH Morbidity
disease MESH coinfection
disease MESH HIV coinfection
drug DRUGBANK Ibuprofen
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Gold
disease MESH weight loss
disease MESH mental disorders
disease MESH lung disease
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Methionine
disease MESH pus
disease MESH latent infection
disease MESH sequelae
drug DRUGBANK Rifampicin
disease MESH death
drug DRUGBANK Aspartame
disease MESH AIDS
disease MESH immune disorders
pathway REACTOME HIV Infection
disease MESH Latent tuberculosis infection
disease MESH Extensively drug resistant tuberculosis
disease MESH infection
drug DRUGBANK Guanosine
drug DRUGBANK Isoniazid
disease MESH hepatitis
drug DRUGBANK Ethambutol
disease MESH blindness
disease MESH hearing loss
disease MESH fatal outcomes
drug DRUGBANK Trestolone
disease MESH Uncertainty
drug DRUGBANK Fenamole
disease MESH undernutrition
disease MESH infectious diseases
drug DRUGBANK Iron
drug DRUGBANK Coenzyme M
drug DRUGBANK Alpha-Linolenic Acid
drug DRUGBANK Dolutegravir
drug DRUGBANK Cabotegravir
drug DRUGBANK Rifapentine
drug DRUGBANK Bedaquiline
disease MESH abnormalities
drug DRUGBANK BCG vaccine
disease MESH pulmonary tuberculosis
drug DRUGBANK Ranitidine
drug DRUGBANK Linezolid
disease MESH adverse drug reactions
disease MESH opportunistic infections
drug DRUGBANK Delamanid
drug DRUGBANK Efavirenz
drug DRUGBANK Nevirapine
drug DRUGBANK Ribostamycin
disease MESH COVID 19 pandemic
drug DRUGBANK Tropicamide
disease MESH diabetes mellitus

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *